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Abstract
Introduction: There is increasing concern regarding the financial burden of cancer on patients 
and their families. This study presents nationally representative estimates of annual out-of-pocket 
(OOP) burden among non-elderly cancer survivors and assesses the association between high OOP 
burden and access to care and preventive service utilization.
Methods: Using the 2008–2012 Medical Expenditure Panel Survey, 4,271 cancer survivors and 
96,780 individuals without a history of cancer were identified, all aged 18–64 years. High annual 
OOP burden was defined as spending > 20% of annual family income on OOP healthcare costs. 
Associations between high OOP burden and access to care were evaluated with multivariable 
logistic regression. Analyses were conducted in 2015.
Results: Compared with individuals without a cancer history, cancer survivors were more likely 
to report a high OOP burden (4.3% vs 3.4%, p=0.009) in adjusted analyses. High OOP burden was 
more common among cancer survivors who were poor (18.4%), with either public insurance 
(7.9%) or uninsured (5.7%), and not working (10.2%). Among cancer survivors, high OOP burden 
was associated with being unable to obtain necessary medical care (19.2% vs 12.5%, p=0.002), 
delaying necessary medical care (21.6% vs 13.8%, p=0.002), and lower breast cancer screening 
rates among age-appropriate women (63.2% vs 75.9%, p=0.02).
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Conclusions: High OOP burden is more common among adults with a cancer history than those 
without a cancer history. High OOP burden was associated with being unable to obtain necessary 
medical care, delaying necessary medical care, and lower breast cancer screening rates among 
women.
Introduction
An estimated 14.5 million Americans with a history of cancer were alive in 2014.1 Previous 
research has shown that cancer survivors face greater healthcare expenditures including out-
of-pocket (OOP) costs compared with individuals without a history of cancer.2–5 High OOP 
costs can reduce access to care, influence clinical practice, and affect treatment choices.6,7 
By creating a financial barrier, OOP payments can lead to reduced use of preventive services 
and uptake of preventive medications.6,8 For example, higher OOP costs are associated with 
lower rates of screening for breast cancer, cervical cancer, and colorectal cancer among 
certain populations.8–10 Reduced access to care among cancer survivors may affect 
surveillance and treatment for disease recurrence, screening for additional cancers, and care 
for the late and lasting effects of cancer treatment.11,12
Limited information exists on OOP burden among cancer survivors at the national level. 
Previous studies have addressed OOP burden among cancer survivors by treatment status, 
rather than among all cancer survivors together,5,13 or have focused on cancer patients aged 
≥ 65 years.13 Additionally, few studies have evaluated the association between OOP burden 
and access to care and preventive service utilization among cancer survivors. This study 
provides a comprehensive analysis of OOP burden among non-elderly adult cancer survivors 
aged 18–64 years. Using nationally representative data, this study examines the prevalence 
of high annual OOP burden and the association between high annual OOP burden and access 
to care and preventive service utilization among non-elderly cancer survivors.
Methods
Data Sources
The study sample was selected from the 2008–2012 Medical Expenditure Panel Survey 
(MEPS) Household Component. The MEPS is a nationally representative sample of the U.S. 
civilian non-institutionalized population that collects detailed information on demographic 
characteristics, health status, income, health insurance, employment, access to care, and 
healthcare expenditures (including OOP expenditures). In-person interviews are conducted 
with an individual who responds for all members of the household. The annual response rate 
ranged from 53.5% to 59.3% during the study years included in the analysis. More-detailed 
information on the MEPS survey design and content is available elsewhere.14,15
Cancer survivors were defined as any person who has ever been diagnosed with cancer. 
Using the 2008–2012 MEPS, 4,271 cancer survivors aged 18–64 years were identified based 
on the question: Has a doctor or other health provider ever told you that you have a cancer or 
malignancy of any kind? The comparison group consisted of the remaining 96,780 adults in 
the same age range who did not report a history of cancer. Similar to previous studies, 
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individuals diagnosed solely with non-melanoma skin cancer were not classified as cancer 
survivors.2,16
Measures
Sociodemographic characteristics of cancer survivors at the time of the survey included: 
time since diagnosis, age, sex, race/ethnicity, educational attainment, marital status, number 
of comorbid conditions, health status, health insurance status, employment status, and family 
income as a percentage of the federal poverty level (FPL). Poor people were defined as 
having family income < 100% FPL, near-poor and low-income people were defined as 
having income 100%–200% FPL, and middle- and high-income people were defined as 
having incomes ≥ 200% of FPL. The number of comorbid conditions was determined 
through a series of questions about whether a doctor or other healthcare professional ever 
told the person that they had any MEPS priority condition, including arthritis, asthma, 
diabetes, emphysema, heart disease, hypertension, stroke, and high cholesterol.
Annual OOP burden was measured as the percentage of OOP costs relative to family 
income. Annual OOP burden included OOP expenditures toward any healthcare service, 
such as coinsurance, copayments, and deductibles. Expenditures include those for cancer 
screening, surveillance, and treatment, as well as medical care for other health conditions. 
Consistent with previous research, OOP burden was defined at the family level, as families 
typically share financial resources.5 Family-level burdens were assigned to individuals 
within the family, allowing the analysis to be conducted at the individual level. Similar to 
previous studies, high OOP burden was defined as having annual OOP spending > 20% of 
annual income.5,17 For families reporting very low or negative incomes (1.8% of cancer 
survivors in the sample), a $100 floor for family income was imposed.5 The results were not 
sensitive to the adjustment.
Several access to care measures were evaluated based on both the availability of care and 
actual utilization of healthcare services in the past year. Access to care measures included:
• having a usual source of care;
• having difficulty getting to a usual source of care;
• being unable to get necessary medical care, dental care, or prescription 
medications; and
• delaying necessary medical care, dental care, or use of prescription medications.
Preventive care was evaluated by examining preventive service use and cancer screening 
services recommended by the U.S. Preventive Services Task Force18 and vaccinations 
recommended by the Advisory Committee on Immunization Practices19 and potentially 
covered by provisions of the Affordable Care Act (ACA). Preventive services included:
• blood pressure screening within the past 2 years;
• cholesterol screening within the past 2 years;
• influenza vaccination in the past year; and
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• breast, cervical, and colorectal cancer screening within recommended screening 
guidelines.
Cancer screening was assessed among age- and gender-eligible men and women. Receipt of 
mammography within the past 2 years among women aged ≥ 40 years was used to identify 
women up to date with breast cancer screening guidelines. Receipt of the Pap test within the 
past 3 years among women aged 21–64 years who had not had their cervix removed was 
used to identify women up to date with cervical cancer screening guidelines. Adherence to 
colorectal cancer screening guidelines was assessed by examining the receipt of a fecal 
occult blood test within 1 year, sigmoidoscopy within the last 5 years, or colonoscopy within 
the last 10 years among men and women aged 50–64 years to identify individuals up to date 
with screening. Individuals with a history of the specific cancer in each analysis were 
excluded to ensure that preventive screenings were captured rather than surveillance.20
Statistical Analysis
Descriptive statistics were calculated for cancer survivors and individuals without a history 
of cancer and compared using chi-square statistics. Multivariable logistic regression models 
controlling for age, sex, race/ethnicity, marital status, education, and number of 
comorbidities were used to compare annual OOP burden among cancer survivors and 
individuals without a history of cancer. Overall results and results stratified by demographic 
factors as well as family income, health insurance, and employment status are presented. 
The adjusted percentages of adults with a high OOP burden are presented as predictive 
margins, which standardize the outcome of each group to the covariate distribution of the 
population.21
Multivariable logistic regression models were used to assess the relationship between high 
OOP burden and access to care and preventive service utilization among cancer survivors. 
Predictive margins were generated to compare these measures among cancer survivors by 
OOP burden status controlling for age, sex, race/ethnicity, marital status, education, and 
number of comorbidities.
Person-level weights were applied to account for the complex study design of the MEPS and 
reflected probability of selection, adjustments for non-response, and post-stratification to 
provide nationally representative estimates. All analyses were conducted using Stata, version 
14.0. Analyses were conducted in 2015.
Results
Cancer survivors were more likely to be older, female, non-Hispanic white, have more 
comorbid conditions, report being in fair or poor health, insured, more likely to be married, 
and more likely not to be working than individuals without a history of cancer (Table 1). 
More than a third of cancer survivors (36.7%) were diagnosed within the past 4 years, and 
39.1% were diagnosed at least 10 years before the survey.
Cancer survivors were more likely to have a high annual OOP burden compared with those 
without a history of cancer. After adjusting for other covariates, 4.3% of cancer survivors 
had a high OOP burden compared with 3.4% of individuals without a history of cancer 
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(p=0.009, Table 2). Among individuals aged 50–64 years, cancer survivors were more likely 
to report a high total OOP burden than individuals without a history of cancer (p=0.02), 
whereas similar rates of high OOP burden were found among those aged 18–49 years 
regardless of their cancer history. Near-poor and low-income along with middle- and high-
income cancer survivors were more likely to have a high annual OOP burden compared with 
individuals in the same poverty level categories but without a history of cancer (p=0.02 and 
p=0.003, respectively). High OOP burden was more common among privately insured 
cancer survivors than among privately insured individuals without a history of cancer (p < 
0.001). High OOP burden was more common among cancer survivors working full-time 
than among individuals without a history of cancer working full-time (p=0.02).
Among cancer survivors, the prevalence of high annual OOP burden varied across a number 
of sociodemographic characteristics. High OOP burden was more common among the poor 
(18.4%) and the near-poor and low-income (4.6%), compared with those with middle and 
high incomes (1.0%). Among cancer survivors, high OOP burden was more common among 
those with public insurance (7.9%) and the uninsured (5.7%) compared with cancer 
survivors with private health insurance (3.2%). High OOP burden was more common among 
cancer survivors who were not working (10.2%) compared with those working part-time 
(4.2%) and those working full-time (1.7%).
Cancer survivors with a high annual OOP burden were more likely to report that they were 
unable to obtain necessary medical care, dental care, or prescription medications (19.2% vs 
12.5%, p=0.002) and delayed necessary care (21.6% vs 13.8%, p=0.002) compared with 
cancer survivors without a high OOP burden (Table 3). Among female cancer survivors, 
breast cancer screening rates were lower among those with a high OOP burden compared 
with those without a high OOP burden (63.2% vs 75.9%, p=0.02).
Discussion
This study demonstrates that cancer survivors are more likely to report a high annual OOP 
burden than individuals without a history of cancer. High annual OOP burden is more 
common among poor cancer survivors, those with public insurance or the uninsured, and 
those not working. Among cancer survivors, high OOP burden is associated with being 
unable to obtain necessary medical care and delaying necessary medical care. Additionally, 
high OOP burden is associated with lower breast cancer screening among age-appropriate 
female cancer survivors.
Although there is literature underscoring the financial burden of cancer survivorship, this is 
the first study to quantify the prevalence of high annual OOP burden and its association with 
access to health care and preventive service utilization among non-elderly cancer survivors 
at the national level. These findings support previous research among cancer survivors 
highlighting the association between higher cost sharing requirements and forgoing or 
delaying medical care.22,23 Access to care is particularly important for cancer survivors, 
given their increased risk of developing other chronic conditions, and long-term adverse 
health effects, including cardiotoxicity, lymphedema, sexual dysfunction, incontinence, pain, 
fatigue, cognitive dysfunction, and psychological distress.24,25 Cancer survivors also have an 
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increased risk of secondary cancers.26,27 Previous studies have highlighted disparities in 
access to care among cancer survivors and the importance of ongoing efforts to improve 
access to care among this population.20
The findings suggest that non-elderly female cancer survivors who reported a high annual 
OOP burden were less likely to report having a recent mammogram. Access to 
recommended preventive care such as breast cancer screening is critical for cancer survivors, 
as they are at an increased risk of developing other cancers and may experience late and 
lasting effects of cancer treatment.25–27 The ACA provides many opportunities for 
prevention. Millions of Americans are now eligible for health insurance coverage through 
the Health Insurance Marketplace and Medicaid expansion in most states, giving them better 
access to health services, including preventive services. The ACA requires non-
grandfathered private health plans and newly eligible beneficiaries of the Medicaid 
expansion to provide coverage without cost sharing for preventive services rated as “A” 
(strongly recommended) or “B” (recommended) by the U.S. Preventive Services Task Force, 
for vaccinations recommended by the Advisory Committee on Immunization Practices, and 
services for infants, women, and children recognized by the Health Resources and Services 
Administration.28 By requiring many plans to cover recommended clinical preventive 
services with no cost sharing to the patient, including screening for breast, cervical, and 
colorectal cancer, the ACA can help reduce financial barriers to the receipt of recommended 
preventive care. However, it is not clear if these changes alone will increase access to care 
among cancer survivors faced with high annual OOP burden. Other barriers such as lack of 
paid sick leave may inhibit the receipt of recommended preventive services.29 Ongoing 
evaluation of access to recommended preventive care will be important as the ACA 
continues to be implemented.30
The current study found that high annual OOP burden is associated with higher rates of 
delaying or forgoing needed medical care among cancer survivors. Delaying or forgoing 
needed medical care among cancer survivors may negatively affect surveillance for disease 
recurrence and care for the late and lasting effects of cancer treatment.11,12 Higher OOP 
costs have also been shown to reduce adherence to cancer treatment.23,31 In a survey of 
medical oncologists, 84% reported that patient OOP spending influenced treatment 
recommendations,7 with 16% acknowledging that they omitted treatment options on the 
basis of their perceptions of patients’ ability to afford treatment.32 The American Society of 
Clinical Oncology Value in Cancer Care Task Force has emphasized the important role of 
patient and provider communication on issues surrounding cost.33 However, many 
physicians may be uncomfortable discussing costs with patients.32 The negative impact on 
the health of cancer patients because of high OOP costs and the financial burden associated 
with treatment related to cancer has been characterized by Ubel and colleagues34 as 
“financial toxicity.” As these authors have explained, providers frequently discuss toxicities 
of treatment, but these discussions typically refer to the physical side effects of treatment. 
Meanwhile, financial toxicities can also have a substantial impact on the quality of life of 
patients and their families. Patients may be faced with choosing between health care related 
to their cancer or paying for daily living expenses.34 Previous research has shown that 
cancer patients were more likely to file bankruptcy than individuals without a history of 
cancer, with the risk of bankruptcy two to five times higher among non-elderly patients 
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given greater variations in employment, income, insurance status, and personal assets.35 
Open dialogue between providers and their patients about these issues could help enable 
informed decision making that carefully considers both expected benefits and potential high 
OOP costs of treatments.35
Limitations
Although the MEPS is one of the most detailed nationally representative data sources 
available to estimate OOP burden among cancer survivors and individuals without a cancer 
history, there are a number of limitations in this study. First, this study relied on household-
reported data, which introduces potential reporting biases. For example, the cancer diagnosis 
question in the MEPS refers to cancer or a malignancy of any kind, which may result in 
identifying those with pre-invasive disease as cancer survivors. To the extent that this is the 
case, the impact of cancer survivorship on OOP burden would be underestimated. Second, 
this study used family pre-tax income rather than post-tax income to compute OOP burden. 
Although post-tax income may be a more accurate measure of financial resources available 
to a family, previous research using the MEPS found that OOP burden prevalence was very 
similar when using pre-tax income, and variations in sociodemographic characteristics were 
virtually identical.36 Lastly, the results only apply to the non-institutionalized civilian adult 
population.
Conclusions
High annual OOP burden is more common among cancer survivors than individuals without 
a cancer history. High OOP burden has the potential to reduce access to care and the 
utilization of preventive services. With the continuing increase in the number of cancer 
survivors and rising healthcare costs, trends in OOP burden among cancer survivors and 
efforts to improve communication between patients and providers about cost will be 
important to monitor and follow.
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Table 1.
Characteristics of Nonelderly Cancer Survivors and Individuals Without a History of Cancer: Medical 
Expenditure Panel Survey, 2008-2012
Characteristics
Cancer survivors,
% (95% CI)
(n=4,271)
Individuals without a history of cancer,
% (95% CI)
(n=96,780) p-value
Time since diagnosis (years)
 0–4 36.7 (34.3–39.1) –
 5–9 22.4 (20.8–24.2) –
 10–19 23.8 (21.9–25.8) –
 ≥ 20 15.3 (13.6–17.1) –
 Missing 1.9 (1.3–2.7) –
Age (years) <0.001
 18–39 15.1 (13.5–16.9) 48.9 (48.0–49.7)
 40–49 20.0 (18.2–21.8) 21.7 (21.2–22.3)
 50–64 64.9 (62.5–67.3) 29.4 (28.6–30.3)
Sex <0.001
 Men 35.0 (32.7–37.3) 50.1 (49.7–50.5)
 Women 65.0 (62.7–67.3) 49.9 (49.5–50.3)
Race/ethnicity <0.001
 Non-Hispanic white 81.3 (79.2–83.1) 63.9 (62.0–65.8)
 Non-Hispanic black 7.9 (6.7–9.2) 12.3 (11.1–13.7)
 Hispanic 7.3 (6.2–8.6) 16.2 (14.6–18.0)
 Non-Hispanic other 3.6 (2.7–4.8) 7.5 (6.6–8.5)
Education <0.001
 Less than high school graduate 11.7 (10.4–13.2) 15.5 (14.8–16.2)
 High school graduate 27.7 (25.7–29.9) 28.4 (27.6–29.3)
 Some college or more 60.4 (58.0–62.9) 55.7 (54.5–56.8)
Marital status <0.001
 Married 61.5 (58.7–64.3) 52.2 (51.3–53.1)
 Not married 38.5 (35.7–41.3) 47.8 (46.9–48.7)
Number of comorbiditiesa <0.001
 None 24.7 (22.5–27.0) 51.6 (50.9–52.3)
 One 24.8 (22.8–27.0) 23.9 (23.4–24.3)
 Two 21.1 (19.1–23.2) 12.9 (12.5–13.3)
 Three or more 29.4 (27.2–31.7) 11.6 (11.2–12.1)
Health status <0.001
 Excellent/Very good 40.8 (38.5–43.0) 62.3 (61.4–63.1)
 Good 31.1 (29.3–33.0) 27.1 (26.4–27.7)
 Fair/Poor 28.1 (26.2–30.0) 10.7 (10.3–11.1)
Health insurance 0.03
 Any private 74.4 (72.3–76.5) 70.5 (69.3–71.7)
 Public only 14.9 (13.3–16.6) 10.6 (10.0–11.3)
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Characteristics
Cancer survivors,
% (95% CI)
(n=4,271)
Individuals without a history of cancer,
% (95% CI)
(n=96,780) p-value
 Uninsured 10.7 (9.3–12.2) 18.9 (17.9–19.8)
Employment status <0.001
 Full time 51.3 (48.5–54.1) 61.4 (60.7–62.1)
 Part time 16.5 (14.8–18.2) 18.9 (18.4–19.4)
 Not working 32.2 (30.0–34.6) 19.7 (19.1–20.3)
Family income <0.001
 Poor (<100% FPL) 12.8 (11.6–14.1) 13.1 (12.4–13.8)
 Near poor and low income
 (100%–200% FPL) 14.6 (13.2–16.1) 16.5 (15.9–17.1)
 Middle and high income (> 200% FPL) 72.5 (70.5–74.4) 70.2 (69.2–71.3)
OOP healthcare expenditures ($)b 2,171 (1,970–2,373) 1,409 (1,360–1,459) <0.001
Note: Boldface indicates statistical significance (p < 0.05). Sample sizes are unweighted.
aComorbidities include arthritis, asthma, diabetes, emphysema, heart disease, hypertension, stroke, and high cholesterol.
bOOP health care expenditures are in 2012 U.S. dollars.
FPL, federal poverty level; OOP, out-of-pocket.
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Table 2.
Prevalence of High OOP Burdena Among Nonelderly Cancer Survivors and Individuals Without a History of 
Cancer: Medical Expenditure Panel Survey, 2008–2012
Characteristics
Cancer survivors,
% (95% CI)b
(n=4,271)
Individuals without a history of cancer,
% (95% CI)b
(n=96,780) p-value
Total 4.3 (3.5–5.0) 3.4 (3.2–3.6) 0.009
Age (years)
 18–39 3.8 (2.3–5.3) 2.8 (2.6–3.0) 0.13
 40–49 3.4 (2.1–4.6) 3.2 (2.9–3.6) 0.81
 50–64 5.7c (4.4–6.9) 4.3 (3.8–4.7) 0.02
Sex
 Men 4.1 (2.9–5.3) 2.9 (2.8–3.1) 0.04
 Women 4.6 (3.8–5.5) 3.8 (3.5–4.0) 0.04
Race/ethnicity
 Non-Hispanic white 4.2 (3.3–5.0) 3.4 (3.1–3.6) 0.046
 Non-Hispanic black 5.3 (3.5–7.1) 4.0 (3.6–4.4) 0.13
 Hispanic 4.3 (2.6–5.9) 3.0 (2.7–3.4) 0.11
 Non-Hispanic other 3.8 (1.1–6.5) 3.2 (2.6–3.8) 0.60
Family income
 Poor (<100% FPL) 18.4d (15.1–21.7) 19.3 (18.2–20.3) 0.63
 Near poor and low income
(100%–200% FPL) 4.6d (3.2–6.1) 3.2 (2.7–3.6) 0.02
 Middle and high income (> 200% FPL) 1.0 (0.5–1.5) 0.5 (0.4–0.6) 0.003
Health insurance
 Any private 3.2 (2.4–4.0) 1.9 (1.7–2.1) <0.001
 Public only 7.9 (5.9–9.8) 8.5 (7.8–9.2) 0.55
 Uninsured 5.7 (4.1–7.3) 6.1 (5.6–6.6) 0.63
Employment status
 Full time 1.7 (1.1–2.2) 1.1 (1.0–1.2) 0.02
 Part time 4.2 (2.5–6.0) 3.1 (2.8–3.5) 0.19
 Not working 10.2e (8.4–12.1) 10.5 (9.8–11.2) 0.77
Note: Boldface indicates statistical significance (p < 0.05).
a
High OOP burden was defined as having annual out-of-pocket expenditures on healthcare services in excess of 20% of annual family income.
b
Predicted marginals from a logistic regression model controlling for age, sex, race/ethnicity, marital status, education, and number of 
comorbidities.
c
High OOP burden was higher among cancer survivors age 50–64 years than among cancer survivors age 18–39 years (p < 0.05).
d
High OOP burden was higher among poor and near poor and low-income cancer survivors than among middle and high-income cancer survivors 
(p < 0.05).
e
High OOP burden was higher among not working cancer survivors than among cancer survivors working full time and part time (p < 0.05).
FPL, federal poverty level; OOP, out-of-pocket.
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Table 3.
Access to Care and Preventive Service Utilization Among Nonelderly Cancer Survivors by OOP Burden: 
Medical Expenditure Panel Survey, 2008–2012
Higha Not high
n % (95% CI)b n % (95% CI)b p-value
Access to care
 Has a usual source of care 272 83.3 (77.9–88.6) 3,999 86.7 (85.2–88.1) 0.18
 Difficult to get to usual healthcare provider (somewhat or
 very difficult) among those with usual source of care 272 9.2 (4.8–13.6) 3,999 6.3 (5.3–7.3) 0.15
 Unable to get necessary medical care, dental care, or
 prescription medication 272 19.2 (14.5–24.0) 3,999 12.5 (11.2–13.7) 0.002
 Delayed any necessary medical care, dental care, or
 prescription medication 272 21.6 (16.3–26.9) 3,999 13.8 (12.4–15.2) 0.002
Preventive services
 Blood pressure checked in last 2 years 272 96.9 (94.3–99.4) 3,999 97.6 (97.0–98.2) 0.52
 Cholesterol checked in last 2 years 272 88.2 (83.6–92.7) 3,999 86.0 (84.6–87.4) 0.38
 Influenza vaccination in the last year 272 45.1 (37.8–52.3) 3,999 49.2 (47.1–51.3) 0.27
Cancer screening (among age- and gender-eligible individuals without the specific cancer)
 Breast cancer screening (mammogram within 2 years)
 among women aged > 40 years) 116 63.2 (52.2–74.3) 1,512 75.9 (73.0–78.9) 0.02
 Cervical cancer screening (Pap test within 3 years) among
 women aged 21–65 years who have not had cervix removed 91 88.9 (81.9–95.9) 1,386 89.8 (87.6–92.0) 0.80
 Colorectal cancer screening (FOBT within 1year,
 sigmoidoscopy within 5 years, or colonoscopy within 10
 years) among adults aged 50–75 years
169 51.1 (42.0–60.1) 2,306 56.1 (53.4–58.9) 0.28
Note: Boldface indicates statistical significance (p < 0.05).
a
High OOP burden was defined as having annual out-of-pocket expenditures on health care services in excess of 20% of annual family income.
b
Predicted marginals from a logistic regression model controlling for age, sex, race/ethnicity, marital status, education, and number of 
comorbidities.
FOBT, fecal occult blood test; OOP, out-of-pocket.
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